Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAG104615 Proof of Concept Study of GSK249320 versus Placebo in Stroke Patients
2012-004494-23Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing GSK249320 with Placebo (2 arms). Primary endpoint: Gait Velocity (primary). Started Jan 2013; status: terminated.
02
Drugs
refanezumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2012-004494-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004494-23.